TY - JOUR
T1 - Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis
AU - Salunkhe, Shubham A.
AU - Chitkara, Deepak
AU - Mahato, Ram I.
AU - Mittal, Anupama
N1 - Funding Information:
The authors acknowledge financial support by Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Govt. of India [CRG/2019/001698] for this work. DC and AM are serving as founding directors of Nanobrid Innovations Private Limited. The authors declare that they have no conflict of interest pertaining to the work outlined in this study.
Funding Information:
The authors acknowledge financial support by Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Govt. of India [CRG/2019/001698] for this work.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/6
Y1 - 2021/6
N2 - Non-alcoholic fatty liver disease (NAFLD) is a cluster of several liver diseases like hepatic steatosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver (NAFL), liver fibrosis, and cirrhosis which may eventually progress to liver carcinoma. One of the primary key factors associated with the development and pathogenesis of NAFLD is diabetes mellitus. The present review emphasizes on diabetes-associated development of liver fibrosis and its treatment using different lipid nanoparticles such as stable nucleic acid lipid nanoparticles, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, self-nanoemulsifying drug delivery systems, and conjugates including phospholipid, fatty acid and steroid-based. We have comprehensively described the various pathological and molecular events linking effects of elevated free fatty acid levels, insulin resistance, and diabetes with the pathogenesis of liver fibrosis. Various passive and active targeting strategies explored for targeting hepatic stellate cells, a key target in liver fibrosis, have also been discussed in detail in this review.
AB - Non-alcoholic fatty liver disease (NAFLD) is a cluster of several liver diseases like hepatic steatosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver (NAFL), liver fibrosis, and cirrhosis which may eventually progress to liver carcinoma. One of the primary key factors associated with the development and pathogenesis of NAFLD is diabetes mellitus. The present review emphasizes on diabetes-associated development of liver fibrosis and its treatment using different lipid nanoparticles such as stable nucleic acid lipid nanoparticles, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, self-nanoemulsifying drug delivery systems, and conjugates including phospholipid, fatty acid and steroid-based. We have comprehensively described the various pathological and molecular events linking effects of elevated free fatty acid levels, insulin resistance, and diabetes with the pathogenesis of liver fibrosis. Various passive and active targeting strategies explored for targeting hepatic stellate cells, a key target in liver fibrosis, have also been discussed in detail in this review.
KW - Conjugates
KW - Diabetes
KW - Lipid nanoparticles
KW - Liposomes
KW - Liver fibrosis
KW - Liver targeting
KW - NAFLD
KW - NASH
KW - NLCs
KW - SLNs
UR - http://www.scopus.com/inward/record.url?scp=85104298412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104298412&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2021.04.003
DO - 10.1016/j.addr.2021.04.003
M3 - Article
C2 - 33831474
AN - SCOPUS:85104298412
VL - 173
SP - 394
EP - 415
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
SN - 0169-409X
ER -